Swiss National Bank
TRAX

Swiss National Bank’s First Tracks Biotherapeutics TRAX Stock Holding History

Swiss National Bank’s Portfolio TRAX Stock Details TRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$984K Buy
+48,900
New +$914K ﹤0.01% 2216

Other funds holding TRAX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
FEG
Financial Enhancement Group Anderson, Indiana $839M AUM 18.63% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Swiss National Bank's TRAX Position: Q2 2026 in Review

Swiss National Bank opened a new position in First Tracks Biotherapeutics (TRAX) in Q2 2026: 48,900 shares worth $984K. The stake represents ﹤0.01% of the portfolio and ranks #2216 among its holdings.

51 funds tracked by Wall St. Rank hold TRAX as of Q2 2026.

  • Swiss National Bank held 48,900 shares of First Tracks Biotherapeutics worth $984K as of Q2 2026.
  • First Tracks Biotherapeutics was a new Swiss National Bank position in Q2 2026.
  • First Tracks Biotherapeutics made up ﹤0.01% of Swiss National Bank's portfolio in Q2 2026, its #2216 holding.
  • 51 funds tracked by Wall St. Rank held First Tracks Biotherapeutics as of Q2 2026.

Based on Swiss National Bank's 13F filing for Q2 2026, filed 11 Aug 2026.